![]() |
Name |
Cis-Dehydrocurvularin
|
Molecular Formula | C16H18O5 | |
IUPAC Name* |
(5S,9Z)-13,15-dihydroxy-5-methyl-4-oxabicyclo[10.4.0]hexadeca-1(12),9,13,15-tetraene-3,11-dione
|
|
SMILES |
C[C@H]1CCC/C=C\C(=O)C2=C(CC(=O)O1)C=C(C=C2O)O
|
|
InChI |
InChI=1S/C16H18O5/c1-10-5-3-2-4-6-13(18)16-11(8-15(20)21-10)7-12(17)9-14(16)19/h4,6-7,9-10,17,19H,2-3,5,8H2,1H3/b6-4-/t10-/m0/s1
|
|
InChIKey |
AVIRMQMUBGNCKS-OAQKJQOQSA-N
|
|
Synonyms |
Cis-Dehydrocurvularin; alpha,beta-Dehydrocurvularin; Dehydrocurvularin, 10,11-; Dehydrocurvularin, cis-; SJ3JA3J8ST; a,b-Dehydrocurvularin_120247; CHEMBL1643635; SCHEMBL23515575; 1095588-70-7; (4S,8Z)-4,5,6,7-Tetrahydro-11,13-dihydroxy-4-methyl-2H-3-benzoxacyclododecin-2,10(1H)-dione; 122400-14-0; 2H-3-Benzoxacyclododecin-2,10(1H)-dione, 4,5,6,7-tetrahydro-11,13-dihydroxy-4-methyl-, (4S,8Z)-; 2H-3-Benzoxacyclododecin-2,10(1H)-dione, 4,5,6,7-tetrahydro-11,13-dihydroxy-4-methyl-, [S-(Z)]-
|
|
CAS | 122400-14-0 | |
PubChem CID | 14314898 | |
ChEMBL ID | CHEMBL1643635 |
Chemical Classification: |
|
|
---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference | |
---|---|---|---|---|---|---|---|---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference |
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name |
Molecular Weight: | 290.31 | ALogp: | 3.0 |
HBD: | 2 | HBA: | 5 |
Rotatable Bonds: | 0 | Lipinski's rule of five: | Accepted |
Polar Surface Area: | 83.8 | Aromatic Rings: | 2 |
Heavy Atoms: | 21 | QED Weighted: | 0.716 |
Caco-2 Permeability: | -4.651 | MDCK Permeability: | 0.00001940 |
Pgp-inhibitor: | 0.001 | Pgp-substrate: | 0.002 |
Human Intestinal Absorption (HIA): | 0.006 | 20% Bioavailability (F20%): | 0.01 |
30% Bioavailability (F30%): | 0.831 |
Blood-Brain-Barrier Penetration (BBB): | 0.223 | Plasma Protein Binding (PPB): | 79.83% |
Volume Distribution (VD): | 0.893 | Fu: | 15.47% |
CYP1A2-inhibitor: | 0.742 | CYP1A2-substrate: | 0.086 |
CYP2C19-inhibitor: | 0.256 | CYP2C19-substrate: | 0.06 |
CYP2C9-inhibitor: | 0.32 | CYP2C9-substrate: | 0.941 |
CYP2D6-inhibitor: | 0.785 | CYP2D6-substrate: | 0.271 |
CYP3A4-inhibitor: | 0.645 | CYP3A4-substrate: | 0.168 |
Clearance (CL): | 16.356 | Half-life (T1/2): | 0.885 |
hERG Blockers: | 0.011 | Human Hepatotoxicity (H-HT): | 0.111 |
Drug-inuced Liver Injury (DILI): | 0.75 | AMES Toxicity: | 0.157 |
Rat Oral Acute Toxicity: | 0.051 | Maximum Recommended Daily Dose: | 0.689 |
Skin Sensitization: | 0.831 | Carcinogencity: | 0.841 |
Eye Corrosion: | 0.185 | Eye Irritation: | 0.352 |
Respiratory Toxicity: | 0.596 |
Similar NPs | Similar Drugs | ||||||
---|---|---|---|---|---|---|---|
NPs ID | NPs 2D Structure | Similarity Score | TTD ID | Drug 2D Structure | Similarity Score | ||
ENC005419 | ![]() |
1.000 | D07MGA | ![]() |
0.322 | ||
ENC005643 | ![]() |
1.000 | D04AIT | ![]() |
0.247 | ||
ENC005417 | ![]() |
1.000 | D0K8KX | ![]() |
0.242 | ||
ENC005418 | ![]() |
0.735 | D00ZFP | ![]() |
0.237 | ||
ENC005138 | ![]() |
0.710 | D0H6QU | ![]() |
0.237 | ||
ENC003140 | ![]() |
0.706 | D0K7LU | ![]() |
0.230 | ||
ENC001430 | ![]() |
0.657 | D04JHN | ![]() |
0.229 | ||
ENC005644 | ![]() |
0.639 | D0J4IX | ![]() |
0.224 | ||
ENC003117 | ![]() |
0.630 | D02NSF | ![]() |
0.224 | ||
ENC005137 | ![]() |
0.613 | D07GRH | ![]() |
0.220 |